Insud Pharma, a global leader in the healthcare industry, has recently acquired the women’s health business of American company Viatris. Led by businessman Hugo Sigman, this acquisition marks a significant milestone for Insud Pharma and solidifies its position as the largest manufacturer of contraceptives in the world. The company views this deal as a strategic move to expand its global leadership in women’s health products and enhance its presence in key markets.
The investment amount for this acquisition was not disclosed, but it is expected to have a significant impact on Insud Pharma’s various businesses. In addition to strengthening their position in key markets like Africa and India, the acquisition also benefits other companies within the group. Exeltis EU gains a boost in its branded product portfolio, Hiromed in the US receives top-notch generic products, and Chemo expands its presence in Africa, where Viatris was a key provider of contraceptives in public health institutions.
With the integration of two hormonal centers of excellence in India, Insud Pharma’s production capacity and quality have increased significantly. They now have a complete network of plants and over 1,800 employees in India, further solidifying their presence in the region.
This acquisition has positioned Insud Pharma as a global leader in the development and supply of products for women’s health. This strategic move not only expands their reach and capacity in various therapeutic areas but also strengthens their industrial presence in key markets. Overall, this acquisition enhances Insud Pharma’s position as a leading player in the global health industry.
